Moderna stock surges as FDA reverses course, agrees to review new flu shot
Thursday, March 12, 2026
2 min read
Canonical SourceUSA
Summary Only
What Changed
Moderna's new flu shot is now under review by the FDA, a reversal of a previous decision, leading to a significant increase in the company's stock price.
Sigvera Intelligence
Source Trust:Discovery
Source Report
The FDA has agreed to review Moderna's new flu shot after previously declining, causing a significant surge in the company's stock price.
Industry Context
Healthtech & Biotech
Where this signal fits in the broader landscape.
115 industry signalsRegulatory & Policy
Source Verification
Verified from official source
Publisher—
Publication DateMar 12, 2026
Source ClassVerified Canonical
Signal Timeline
First ReportedMar 12, 2026
IndexedMar 12, 2026
PublishedMar 12, 2026
https://finance.yahoo.com/news/moderna-stock-surges-as-fda-reverses-course-agrees-to-review-new-flu-shot-162043049.html
Read Full SourceGet cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
Sign In